The treatment of advanced neovascular AMD (“wet ̈ variant) consists mainly on the use of monoclonal antibodies against vascular endothelial growth factor (VEGF) but the  ̈dry ̈ variant of AMD has no reliable treatment yet. Here, VEGFA is linked to age-related macular degeneration.